Owkin a prominent AIbiotech firm has expanded into the DACH region by forming partnerships with nine leading institutions These include Charit Universittsmedizin Berlin
Radionetics Oncology a biotechnology company focused on developing innovative small molecule radiopharmaceuticals for targeting G proteincoupled receptors to treat solid tumors has announced a strategic partnership with Eli Lilly and Company The collaboration includes an upfront cash payment
Signet Therapeutics a biotech company specializing in organoid disease models and AI for targeted cancer therapy announced FDA approval of its Investigational New Drug application for sigx
TauRx Pharmaceuticals Ltd has submitted a UK Marketing Authorisation Application for hydromethylthionine mesylate targeting mild cognitive impairment and mild
Waypoint Bio a biotechnology company has secured million in seed funding led by Hummingbird Ventures with participation from Recode Ventures and Fifty Years The company focuses on developing
AQEMIA a leader in AIdriven drug discovery has achieved a significant research milestone in collaboration with Servier an international pharmaceutical company targeting an unmanageable
Fresenius via its operating company Fresenius Kabi announced today the immediate availability in the US of its biosimilar Tyenne in a subcutaneous
Vertex Pharmaceuticals Incorporated today announced that the US Food and Drug Administration has accepted its New Drug Application for investigational
Heron Therapeutics Inc a commercialstage biotechnology company today announced that the FDA acknowledged the receipt of the Companys Prior
The US Food and Drug Administration approved Kisunla Eli Lilly and Companys Alzheimers treatment for adults with early symptomatic Alzheimers disease which includes people with mild cognitive impairment as well as people
Boston, MA, USA
Boston, MA, USA
Telangana, India
Hyderabad, India
Boston, MA, USA
Boston, USA
London, UK
Kuala Lumpur, Malaysia
Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.
Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.
Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.
Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.
Kate, Editorial Team at Pharma Focus Europe, leverages her extensive background in pharmaceutical communication to craft insightful and accessible content. With a passion for translating complex pharmaceutical concepts, Kate contributes to the team's mission of delivering up-to-date and impactful information to the global Pharmaceutical community.
It can rightly be said that the business of pharmaceuticals is very sensitive and crucial since business is all about the manufacturing of change for the purpose of ridding the world of diseases
Currently there is a great advancement in the use of technological solutions particularly under the modern pharma digital era Therefore with increase in knowledge dissemination through internet among the citizenry due to enhanced technology
Technology has revolutionized every aspect of our lives and healthcare is no exception From electronic health records EHRs to telemedicine and wearable devices advancements in technology
Cell therapy involves the use of living cells to treat medical conditions These cells can be sourced from a patient or a donor and are often manipulated or engineered to enhance their therapeutic effects
Drug safety is a paramount concern for pharmaceutical companies worldwide Ensuring the safety and efficacy of medications is not only a legal requirement but also a moral obligation towards patient welfare
The healthcare industry is continually evolving driven by technological advancements and innovative approaches to patient care Among the most significant developments is the symbiotic relationship between medical devices
Lisa Bero Fieke Oostvogel Peter Bacchetti Kirby Lee Clinical Pharmacy and Health Policy University of California San Francisco California United States of America Department of Mathematics University of Leiden The Netherlands Department of Epidemiology and Biost
A Personalized Cancer Monitoring PCM technology designed for minimally invasive monitoring and recurrence surveillance for earlystage cancer has been launched by ArcherDX
Biotechnology an industry at the forefront of scientific innovation and transformative healthcare solutions
Recent industry pressures brought on by the global COVID pandemic provided critical lessons for the life sciences industry
Today there are more than known rare diseases defined by the European Union as conditions that affect less than in people
Continuous manufacturing methods have been extensively demonstrated to have a significant impact on improving quality
In drug discovery AI is being used to predict the efficacy and safety of potential drug candidates identify new therapeutic targets and optimize clinical trial designs
Currently Im VP of Advanced Drug Delivery at Novo Nordisk Much of my role focuses on understanding drug delivery needs across our Research Early Development portfolio and identifying novel technologies